Jade Biosciences, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Jade Biosciences, Inc. (JBIO) had Debt Securities, Available-for-sale, Unrealized Loss Position of $2.02 million as of 2024-12-31, per its 10-Q filed 2025-04-25.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2025-04-25
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $2.02M.
- 2024-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $54.80M.
- 2024-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $51.35M.
- 2023-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $20.99M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2024-12-31 | $2.02M 10-Q · filed 2025-04-25 |
| 2024-06-30 | $54.80M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $51.35M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $20.99M 10-K · filed 2025-03-27 |
| 2023-09-30 | $88.03M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $77.94M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $72.11M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $84.70M 10-K · filed 2024-03-25 |
| 2021-12-31 | $69.16M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |